—] Shares BIND Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
AMENDED AND RESTATED CONSULTING AGREEMENT (Omid Farokhzad)Consulting Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
This Amended and Restated Consulting Agreement dated as of July 12, 2007 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Omid Farokhzad (the “Consultant”).
MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and BIND Biosciences, Inc. (“COMPANY”), a Delaware corporation, with a principal place of business at 101 Binney Street, Cambridge, MA 02142.
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
This Fourth Amended and Restated Investors’ Rights Agreement dated as of November 7, 2011 (this “Agreement”), is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser,” and collectively, the “Purchasers”); the persons and entities listed on Schedule B (collectively, the “Licensor Stockholders”); the entities listed on Schedule C (the “Founder Trusts”) and Omid Farokhzad, Paul Goldenheim and Robert S. Langer, Jr. (each individually a “Founder,” collectively the “Founders,” and together with the Licensor Stockholders and the Founder Trusts, the “Initial Stockholders”).
FOURTH AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
This Fourth Amended and Restated Voting Agreement dated as of November 7, 2011 (this “Agreement”) is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser” and collectively, the “Purchasers”); Omid Farokhzad, Paul Goldenheim and Robert S. Langer, Jr. (each, a “Founder,” and collectively, the “Founders”); the persons listed on Schedule B (collectively, the “Executive Officers”); and the persons listed on Schedule C (the “Other Stockholders”). The Purchasers, the Founders, the Executive Officers and the Other Stockholders are (together with and any other persons or entities that become parties to this Agreement after the date hereof in accordance with Section 12.8 or 12.9 hereof) referred to in this Agreement individually as a “Stockholder” and collectively as the “Stockholders.”
CONSULTING AGREEMENT (Robert S. Langer, Jr.)Consulting Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
This Consulting Agreement dated as of October 31, 2006 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Robert S. Langer, Jr. (the “Consultant”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTSeparation Agreement and Release • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of June, 2013 is entered into by BIND Therapeutics, Inc. (f/k/a BIND Biosciences, Inc.), a Delaware corporation (the “Company”), and Daniel S. Lynch, an individual residing at 7 Calhoun Drive, Greenwich, Connecticut 06831 (the “Executive”).
